A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1

NIH RePORTER · NIH · R01 · $350,480 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY High expression of the transcriptional co-activator Meningioma-1 (MN1) is common in AML, and associated with a poor prognosis. Forced expression of MN1 in murine hematopoietic progenitors induces an aggressive leukemia. We recently discovered that the primary interaction partner of MN1 is the BAF nucleosome- positioning complex. MN1 stabilizes BAF on chromatin. MN1 binding is associated with sustained active enhancer chromatin at enhancers regulating a hematopoietic stem/progenitor program. We hypothesize that MN1 stabilizes promoter-enhancer contacts at these sites through a BAF dependent mechanism. The goal of this project is to uncover the molecular mechanism of MN1-mediated leukemic transformation. A better understanding of how MN1 causes leukemia may identify opportunities for targeted therapies in a patient population who is failing conventional AML therapy.

Key facts

NIH application ID
10445974
Project number
1R01CA262260-01A1
Recipient
CHILDREN'S HOSP OF PHILADELPHIA
Principal Investigator
KATHRIN M BERNT
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$350,480
Award type
1
Project period
2022-04-01 → 2027-03-31